


www.Lung-Map.org

Volume 6 | Winter 2017



Just in time for Lung Cancer Awareness Month, patients can enroll in a new Lung-MAP sub-study. Here's what you need to know:



This is a non-matched, Phase II study for patients whose lung cancer has progressed during or after treatment with PD-1/PD-L1 inhibitors, a new class of immunotherapy drugs. To be eligible to enroll in this sub-study, PD-1/PD-L1 inhibitors must be a patient's most recent line of treatment. S1400F is testing the combination of durvalumab and tremelimumab, drugs being developed by AstraZeneca and MedImmune. These immunotherapies are known as immune checkpoint inhibitors, which bind to cancer cells and induce an immune attack on those cells. This drug combination is also being tested in non-small cell lung cancer.

For more information on S1400F, view the protocol abstracts on www.swog.org or www.swog.org or www.ctsu.org.

Lung-MAP Lands in Japan

Lung-MAP co-chair Dr. Roy Herbst of Yale Cancer Center gave a trial update at the World Conference on Lung Cancer 2017.

held in Yokohama, Japan from October 14-18. Herbst reported on progress and plans:

- 740 study sites,
- 13 genetic alterations identified in patients.
- four sub-studies completed,
- two actively accruing, and two in development.

Lung-MAP Active Study Webinar



Lung-MAP

Active Study Webinar
Get the study status and get your

questions answered. Register for the webinar here: <u>Join WebEx Meeting</u>

Thursday, December 7, 2017 2:00pm Eastern Standard Time Host: Stacey Adam Meeting number: 625 529 541 Meeting password: lungmap

Audio connection: Call-in toll number (US/Canada) 1-650-479-3208 Access code: 625 529 541

Thanks for your efforts in collecting and entering retrospective data on S1400A and S1400I! For questions, please contact S1400question@crab.org

The launch of these two new sub-studies is in progress, and more are on the way. The new treatments will include armed antibodies, drug combinations, and immunotherapy combinations.












STATUS REPORT





Top Accruing Sites

Source: CTSU, As of 11/10/17

Site

- 1. Heartland Cancer Research NCORP
- 2. Southeast Clinical Oncology Research (SCOR) Consortium NCORP
- 3. Kaiser Permanente NCI Community Oncology Research Program
- 4. Roswell Park Cancer Institute LAPS
- 5. Georgia NCI Community Oncology Research Program
- 6. Duke University Duke Cancer Institute LAPS
- 7. Michigan Cancer Research Consortium NCORP
- 8. Yale University Yale Cancer Center LAPS
- 9. Indiana University Melvin and Bren Simon Cancer Center LAPS
- 10. Metro Minnesota Community Oncology Research Consortium
- 11. Wisconsin NCI Community Oncology Research Program
- 12. University of Pennsylvania/Abramson Cancer Center
- 13. University of Texas MD Anderson Cancer Center LAPS
- 13. Wichita NCI Community Oncology Research Program
- 14. UC Davis Comprehensive Cancer Center LAPS
- 14. CWRU Case Comprehensive Cancer Center LAPS
- 15. Fred Hutchinson Cancer Research Center LAPS
- 15. VCU Massey Cancer Center Minority Underserved NCORP
- 16. University of Pittsburgh Cancer Institute LAPS
- 17. University of Oklahoma Health Sciences Center LAPS

Pre-Screening

Don't Forget Pre-Screening

Patients with Stage IV or recurrent disease are eligible for pre-screening prior to progression on their current line of therapy. Patient benefits include:

- Free genetic tumor test
- Tumor testing nets important information about their disease
- "Plan B" if initial treatment fails

HAVE A STORY IDEA FOR THIS NEWSLETTER?

Contact Wendy Lawton at lawtonw@ohsu.edu

STUDY CONTACTS GOT A LUNG-MAP QUESTION? HERE'S WHO TO CALL.

Eligibility + Imaging + Data Submission:

Data Operations, (206) 652-2267 S1400Question@crab.org

Protocol + Regulatory:

SWOG Operations Office, (210) 614-8808, ext. 1019 cmiwa@swog.org

Treatment + Toxicity Study Distribution Lists:

S1400: S1400MedicalQuery@swog.org S1400F: S1400FMedicalQuery@swog.org S1400G: S1400GMedicalQuery@swog.org S1400I: S1400IMedicalQuery@swog.org

Funding Questions:

Group Chair's Office, funding@swog.org For additional information, see funding memos.